JP2010526102A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526102A5
JP2010526102A5 JP2010506692A JP2010506692A JP2010526102A5 JP 2010526102 A5 JP2010526102 A5 JP 2010526102A5 JP 2010506692 A JP2010506692 A JP 2010506692A JP 2010506692 A JP2010506692 A JP 2010506692A JP 2010526102 A5 JP2010526102 A5 JP 2010526102A5
Authority
JP
Japan
Prior art keywords
composition
hydrochloride
bernakalant
mammal
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010506692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010526102A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/062551 external-priority patent/WO2008137778A2/en
Publication of JP2010526102A publication Critical patent/JP2010526102A/ja
Publication of JP2010526102A5 publication Critical patent/JP2010526102A5/ja
Pending legal-status Critical Current

Links

JP2010506692A 2007-05-04 2008-05-02 イオンチャネル調節化合物の制御放出経口製剤および不整脈を予防するための関連する方法 Pending JP2010526102A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91612907P 2007-05-04 2007-05-04
US6615607P 2007-08-01 2007-08-01
US3411908P 2008-03-05 2008-03-05
US3719808P 2008-03-17 2008-03-17
PCT/US2008/062551 WO2008137778A2 (en) 2007-05-04 2008-05-02 Controlled release oral formulations of ion channel modulating compounds and related methods for preventing arrhythmia

Publications (2)

Publication Number Publication Date
JP2010526102A JP2010526102A (ja) 2010-07-29
JP2010526102A5 true JP2010526102A5 (https=) 2011-06-23

Family

ID=39691347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010506692A Pending JP2010526102A (ja) 2007-05-04 2008-05-02 イオンチャネル調節化合物の制御放出経口製剤および不整脈を予防するための関連する方法

Country Status (19)

Country Link
US (3) US20080312309A1 (https=)
EP (3) EP2462933A1 (https=)
JP (1) JP2010526102A (https=)
KR (1) KR20100017648A (https=)
CN (1) CN101711174A (https=)
AU (1) AU2008247508B2 (https=)
BR (1) BRPI0810697A2 (https=)
CA (1) CA2686396A1 (https=)
CO (1) CO6241136A2 (https=)
CR (1) CR11117A (https=)
EA (1) EA200971025A1 (https=)
EC (1) ECSP099777A (https=)
IL (1) IL201934A0 (https=)
MA (1) MA31664B1 (https=)
MX (1) MX2009011929A (https=)
NI (1) NI200900196A (https=)
NZ (1) NZ581351A (https=)
TN (1) TN2009000461A1 (https=)
WO (1) WO2008137778A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US20110198492A1 (en) * 2010-02-18 2011-08-18 Black David L Detection and Quantitation of Pain Medications in Oral Fluid Specimens

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69126064T2 (de) 1990-06-22 1997-08-28 Hoffmann La Roche Nachweis von schwachen Metabolisierungsreagentien von Drogen
US5891696A (en) 1996-08-02 1999-04-06 Panvera Corporation Compositions for cytochrome P450 biotransformation reactions
JP3176342B2 (ja) 1997-08-13 2001-06-18 ファイザー製薬株式会社 薬剤代謝の評価方法及び前記方法用の試薬組成物
CA2326777C (en) * 1998-04-01 2011-12-20 Nortran Pharmaceuticals Inc. Aminocyclohexyl ether compounds and uses thereof
US7507545B2 (en) * 1999-03-31 2009-03-24 Cardiome Pharma Corp. Ion channel modulating activity method
US7524879B2 (en) * 2000-10-06 2009-04-28 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
US7057053B2 (en) * 2000-10-06 2006-06-06 Cardiome Pharma Corp. Ion channel modulating compounds and uses thereof
EP1281755A3 (en) * 2001-07-31 2003-06-18 Pfizer Products Inc. Variants of the human cyp2d6 gene
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US7345086B2 (en) * 2003-05-02 2008-03-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
WO2004098525A2 (en) * 2003-05-02 2004-11-18 Cardiome Pharma Corp. Uses of ion channel modulating compounds
CA2524323C (en) * 2003-05-02 2012-05-15 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US20080063707A1 (en) * 2003-05-02 2008-03-13 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
US20090041841A1 (en) * 2003-05-02 2009-02-12 Cardiome Pharma Corp. Controlled release tablet formulations for the prevention of arrhythmias
WO2005018635A2 (en) * 2003-08-07 2005-03-03 Cardiome Pharma Corp. Ion channel modulating activity i
US7345087B2 (en) 2003-10-31 2008-03-18 Cardiome Pharma Corp. Aminocyclohexyl ether compounds and uses thereof
US7754897B2 (en) * 2005-06-15 2010-07-13 Cardiome Pharma Corp. Synthetic processes for the preparation of aminocyclohexyl ether compounds
US7705036B2 (en) * 2004-04-01 2010-04-27 Cardiome Pharma Corp. Deuterated aminocyclohexyl ether compounds and processes for preparing same
ES2483940T3 (es) * 2004-11-08 2014-08-08 Cardiome Pharma Corp. Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
WO2009018547A1 (en) * 2007-08-01 2009-02-05 Cardiome Pharma Corp. Extended release formulations containing an ion-channel-modulating compound for the prevention of arrhythmias

Similar Documents

Publication Publication Date Title
IL179454A (en) Coated tablet formulation comprising saxagliptin and method for preparing the same
JP2008501025A5 (https=)
US20050059690A1 (en) Method of treating acute pain with a unitary dosage form comprising ibuprofen and oxycodone
WO2003005967A2 (en) Dual release levodopa ethyl ester and decarboxylase in controlled release core
EP3781135A2 (en) Solid oral pharmaceutical compositions comprising sitagliptin
JP2010526102A5 (https=)
EP4008317A1 (en) Solid pharmaceutical formulations of amorphous dapagliflozin
JP2022529189A (ja) 持続放出製剤
CN1649569A (zh) 控释剂型
CA3185535A1 (en) The process for the preparation of a film coated tablet comprising linagliptin and metformin
EP2867199B1 (en) Stable compositions of fesoterodine
US20080187582A1 (en) Pharmaceutical Composition Comprising an Indolylmaleimide Derivative
US20230172863A1 (en) Modified-release dosage forms of ruxolitinib
US20120035177A1 (en) Tablet formulation for p38 inhibitor and method
WO2022225489A1 (en) A bilayer tablet formulation comprising amorphous dapagliflozin and metformin
CA3085455A1 (en) A solid oral dosage form comprising linagliptin
US20130189358A1 (en) Saxagliptin pharmaceutical formulations
SG190326A1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
US20090018181A1 (en) Drug composition for prevention or inhibition of advance of diabetic complication
EP3439639A1 (en) Stabilized solid dosage form
EP2875807A1 (en) Tablet formulation of colesevelam
US20130251795A1 (en) Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
US20250221937A1 (en) Stable pharmaceutical compositions comprising erdafitinib
US20100081702A1 (en) Pharmaceutical composition for prophylaxis or treatment of hepatitis
WO2009080762A2 (en) Pharmaceutical composition